Vanguard Capital Management
STLN

Vanguard Capital Management’s Starling Oncology STLN Stock Holding History

Vanguard Capital Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.7M Sell
3,265,531
-211,250
-6% -$887K ﹤0.01% 2509
2026
Q1 		$10.7M Buy
+3,476,781
New +$10.7M ﹤0.01% 2700

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return

Vanguard Capital Management's STLN Position: Q2 2026 in Review

Vanguard Capital Management reduced its Starling Oncology (STLN) stake by 6.1% in Q2 2026, selling an estimated $887K and leaving 3,265,531 shares worth $17.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2509.

Vanguard Capital Management first reported a position in STLN in Q1 2026 and has held it in 2 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Vanguard Capital Management held 3,265,531 shares of Starling Oncology worth $17.7M as of Q2 2026.
  • Vanguard Capital Management sold 211,250 Starling Oncology shares in Q2 2026, an estimated $887K.
  • Starling Oncology made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2509 holding.
  • Vanguard Capital Management first reported a position in Starling Oncology in Q1 2026 and has held it in 2 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.